KRSA logo

Korsana Biosciences, Inc.

KRSA
Healthcare|Biotechnology|US
$31.05
+0.62 (+2.04%)
DCF Value
$6.75
Tangible Book / Share
$685.88
Cash / Share
$751.25

About

Korsana Biosciences, Inc. is a clinical-stage biotechnology company developing therapies for neurodegenerative diseases. Its lead program, KRSA-028, is an investigational shuttled antibody targeting amyloid beta for the treatment of Alzheimer's disease. The company became publicly traded in September 2026 through a merger with Cyclerion Therapeutics, Inc.

Stock Price

+162.5%(1Y)
1M
-7.3%
3M
+24.2%
6M
+43.1%
YTD
+249.3%
1Y
+146.4%
3Y
+81.8%
5Y
-92.3%

Pipeline Summary

0 total trials
0
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4

Key Facts

Market Cap$145.4M
Employees1 (+0% YoY)
CEOJonathan Violin
IPO DateSep 9, 2026
Beta1.84
52-Week Range$7.189 – $59.36
Avg Volume54,517
ExchangeNASDAQ
Websitekorsana.com

Ownership

Shares Outstanding4.7M

Recent Insider Trades

Pernice Michelle PatriciaAWARD
Sep 9, 202648,445 shares @ $26.20
Shah Nimish PAWARD
Sep 9, 202648,445 shares @ $26.20
Fairmount Funds Management LLCAWARD
Sep 9, 202648,445 shares @ $26.20
Gottesdiener AndrewAWARD
Sep 9, 202648,445 shares @ $26.20
Violin JonathanOTHER
Sep 8, 20260 shares

Peers

ADXNAddex Therapeutics Ltd
$3.6M
AIMAIM ImmunoTech Inc.
$6.2M
KTTAPasithea Therapeutics Corp.
$19.3M
NBYNovaBay Pharmaceuticals, Inc.
$39.1M
PLRZPolyrizon Ltd.
$12.4M
QNRXQuoin Pharmaceuticals, Ltd.
$7.3M
RADXRadiopharm Theranostics Limited
$1.2M
TCRTAlaunos Therapeutics, Inc.
$6.0M

Recent News

Korsana Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Nov 5, 2026 · globenewswire.com
Korsana Biosciences to Participate in Upcoming Investor Conferences
Nov 2, 2026 · globenewswire.com
Korsana Biosciences Completes Closing of Merger with Cyclerion Therapeutics and Previously Announced Private Placement of $380 Million
Sep 8, 2026 · globenewswire.com
Data last updated: Nov 9, 2026, 04:18 AM